Metformin with Versus without Concomitant Probiotic Therapy in Newly Diagnosed Patients with Type 2 Diabetes or Prediabetes: A Comparative Analysis in Relation to Glycemic Control, Gastrointestinal Side Effects, and Treatment Compliance

Background: To evaluate the impact of concomitant use of probiotic BB-12 in metformin-treated patients with type 2 diabetes or prediabetes on glycemic control, metformin-related gastrointestinal side effects, and treatment compliance. Methods: A total of 156 patients (mean [standard deviation] age:...

Full description

Saved in:
Bibliographic Details
Published in:The Turkish Journal of Gastroenterology 2022-11, Vol.33 (11), p.925-933
Main Authors: Sahin, Kubra, Sahinturk, Yasin, Koker, Gokhan, Koker, Gulhan Ozcelik, Bostan, Feyzi, Kok, Mehmet, Uyar, Seyit, Cekin, Ayhan Hilmi
Format: Article
Language:English
Subjects:
Care and treatment
Complications and side effects
Dosage and administration
GASTROINTESTINAL TRACT
Metformin
Original
Patient outcomes
Prediabetic state
Probiotics
Type 2 diabetes
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: To evaluate the impact of concomitant use of probiotic BB-12 in metformin-treated patients with type 2 diabetes or prediabetes on glycemic control, metformin-related gastrointestinal side effects, and treatment compliance. Methods: A total of 156 patients (mean [standard deviation] age: 50.9 [9.9 years], 74.4% females) with newly diagnosed type 2 diabetes or prediabetes were randomly assigned to receive either metformin alone (n = 84, MET group) or metformin plus Bifidobacterium animalis subsp. lactis (BB-12) probiotic (n = 72, MET-PRO group). Data on body mass index (kg/[m.sup.2]), fasting blood glucose (mg/dL), blood lipids, and glycated hemoglobin (HbA1c) levels were recorded at baseline and at the third month of therapy. Data on gastrointestinal intolerance symptoms and treatment noncompliance were also recorded during post-treatment week 1 to week 4. Results: MET-PRO versus MET therapy was associated with a significantly higher rate of treatment compliance (91.7% vs 71.4%, P = .001), greater reduction from baseline HbA1c values (0.9 [0.4-1.6] vs 0.4 [0-1.6] %, P < .001) and lower likelihood of gastrointestinal intolerance symptoms, including abdominal pain (P = .031 to
ISSN:1300-4948
2148-5607
DOI:10.5152/tjg.2022.211063